Health Catalyst Reports Third Quarter 2026 Results

Health Catalyst, Inc. (HCAT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Health Catalyst Reports Third Quarter 2026 Results SALT LAKE CITY, UT, November 5, 2026 — Health Catalyst, Inc. (“Health Catalyst,” Nasdaq: HCAT), a healthcare intelligence company designed to accelerate measurable improvement for health systems, today reported finan

Event · Earnings
Also in this documentGuidance · reaffirm · $246M–$249M

Facts are quoted from the filing text and checked against it.

Original reporting
Published Nov 5, 2026, 9:07 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 9:10 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$HCAT
Neutral
high confidence
Mentioned
$HCAT
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$HCATNeutralMed
01

Why it matters

The Q3 release shows a sharp revenue drop and a near‑zero adjusted EBITDA, while reaffirming full‑year outlook, suggesting short‑term headwinds but no change to long‑term targets.

02

Market read

First‑time disclosure of Q3 results and guidance provides actionable data for traders; the earnings miss may trigger short‑term downside.

03

What to watch

The $65.9 M gain from the Vitalware divestiture masks underlying operating weakness.

Relevance 7/10Novelty 7/10Timing: after‑market today
AlphAI · Earnings readHCAT · Third quarter 2026 · ended September 30, 2026

Health Catalyst Reports Third Quarter 2026 Results

↓Weak quarter

Third-quarter total revenue, gross profit, gross margin and Adjusted EBITDA declined year over year, while reported GAAP net income was driven largely by the $65.9 million gain on sale of the Vitalware Business.

Revenue
$56.3M
(26)% y/y
Technology, three months ended September 30, 2026
$40.7M
Gross margin · GAAP
31%
EPS · non-GAAP
$ (0.03)
Full year of 2026 outlook
$246 million to $249 million

Actuals vs. the company’s prior outlook

from its previous release
MetricGuidedReportedVerdict
Revenue, Q3 2026$55 million to $56 million for the third quarter of 2026$ 56,283 (in thousands)above
Adjusted EBITDA, Q3 2026$0 to $0.5 million for the third quarter of 2026$ 779 (in thousands)above

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Total revenue, three months ended September 30, 2026GAAP$56.28M–(26)%
Gross profit, three months ended September 30, 2026GAAP$17.34M–(42)%
Gross margin, three months ended September 30, 2026GAAP31%––
Income from operations, three months ended September 30, 2026GAAP$50.14M––
Net income (loss) attributable to common stockholders, three months ended September 30, 2026GAAP$40.50M–282%
Net income (loss) per share, basic, three months ended September 30, 2026GAAP$ 0.54––
Net income (loss) per share, diluted, three months ended September 30, 2026GAAP$ 0.53––
Adjusted Gross Profit, three months ended September 30, 2026non-GAAP$24.91M–(38)%
Adjusted Gross Margin, three months ended September 30, 2026non-GAAP44%––
Adjusted EBITDA, three months ended September 30, 2026non-GAAP$779K–(94)%
Adjusted Cost of Revenue, three months ended September 30, 2026non-GAAP$31.37M––
Adjusted Operating Expenses, three months ended September 30, 2026non-GAAP$24.13M––
Adjusted Operating Expenses as a % of revenue, three months ended September 30, 2026non-GAAP43%––
Adjusted Net Income (Loss), three months ended September 30, 2026non-GAAP−$2.55M––
Adjusted Net Income (Loss) per share, basic and diluted, three months ended September 30, 2026non-GAAP$ (0.03)––
Total revenue, nine months ended September 30, 2026GAAP$197.5M––
Income (loss) from operations, nine months ended September 30, 2026GAAP−$92.82M––
Net income (loss) attributable to common stockholders, nine months ended September 30, 2026GAAP−$111.1M––
Net cash provided by (used in) operating activities, nine months ended September 30, 2026GAAP$16.91M––

Segments

SegmentRevenueq/qy/y
Technology, three months ended September 30, 2026No segment-specific driver was provided.$40.69M––
Professional services, three months ended September 30, 2026No segment-specific driver was provided.$15.60M––
Technology, nine months ended September 30, 2026No segment-specific driver was provided.$138.9M––
Professional services, nine months ended September 30, 2026No segment-specific driver was provided.$58.58M––

Amounts quoted below without a unit are in thousands, as in the filing’s tables. Per-share figures are as printed.

Full year of 2026 outlook

  • Revenue$246 million to $249 million
  • NoteAdjusted EBITDA of $18 million to $18.5 million.

Capital returns

  • Repurchase of common stock: $ — for the nine months ended September 30, 2026, compared with $ (5,000) (in thousands) for the nine months ended September 30, 2025.

What drove it

  • The divestiture of the Vitalware Business on July 31, 2026.
  • Headwinds related to the migration from DOS to Ignite.
  • Cost reduction initiatives partially offset the effects on total revenue, gross profit, gross margin, Adjusted Gross Profit, Adjusted Gross Margin, and Adjusted EBITDA.
  • The $65.9 million gain on sale of the Vitalware Business largely drove third-quarter net income.

Concerns

  • Total revenue decreased (26)% year over year to $ 56,283 (in thousands).
  • Adjusted EBITDA decreased (94)% year over year to $ 779 (in thousands).
  • GAAP gross margin was 31%, compared with 39% in the prior-year quarter, and Adjusted Gross Margin was 44%, compared with 53%.
  • Professional services generated gross profit of $ (479) (in thousands) and gross margin of (3)% in the third quarter of 2026.
  • Adjusted Net Income (Loss) was $ (2,549) (in thousands), compared with $ 4,306 (in thousands).
  • Goodwill impairment was $ 122,548 (in thousands) for the nine months ended September 30, 2026.

What to watch

  • Client retention and the path to generating durable, profitable revenue.
  • Client churn or down-selling in connection with the migration to Ignite or otherwise.
  • The full-year 2026 outlook for total revenue of $246 million to $249 million and Adjusted EBITDA of $18 million to $18.5 million.
  • The effect of the Vitalware divestiture on revenue and profitability.

Balance sheet and cash flow

  • Cash and cash equivalents: $ 53,746 (in thousands) as of September 30, 2026, compared with $ 50,814 (in thousands) as of December 31, 2025.
  • Short-term investments: $ 25,245 (in thousands) as of September 30, 2026, compared with $ 44,918 (in thousands) as of December 31, 2025.
  • Long-term debt, net of current portion: $ — as of September 30, 2026, compared with $ 151,624 (in thousands) as of December 31, 2025.
  • Repayment of debt: $ (163,960) (in thousands) for the nine months ended September 30, 2026.
  • Proceeds from sale of business: $ 144,455 (in thousands) for the nine months ended September 30, 2026.
  • Capitalization of internal-use software: $ (13,584) (in thousands) for the nine months ended September 30, 2026.
  • Purchases of property and equipment: $ (839) (in thousands) for the nine months ended September 30, 2026.
  • Net cash provided by investing activities: $ 149,382 (in thousands) for the nine months ended September 30, 2026.
  • Net cash used in financing activities: $ (163,331) (in thousands) for the nine months ended September 30, 2026.

Analysis

Health Catalyst reported third-quarter total revenue of $ 56,283 (in thousands), down (26)% from $ 76,323 (in thousands). Technology revenue was $ 40,686 (in thousands) and professional-services revenue was $ 15,597 (in thousands), compared with $ 52,051 (in thousands) and $ 24,272 (in thousands), respectively, in the prior-year quarter. The company said the year-over-year decline in total revenue primarily reflected the July 31, 2026 divestiture of the Vitalware Business and headwinds from the migration from DOS to Ignite, partly offset by cost reduction initiatives.

Profitability deteriorated in the operating business. GAAP gross profit fell (42)% to $ 17,345 (in thousands), with gross margin at 31% versus 39%. Adjusted Gross Profit fell (38)% to $ 24,913 (in thousands), and Adjusted Gross Margin was 44% versus 53%. Adjusted EBITDA declined (94)% to $ 779 (in thousands) from $ 12,000 (in thousands). Professional services posted $ (479) (in thousands) of gross profit and a (3)% gross margin, while technology generated $ 17,824 (in thousands) of gross profit and a 44% gross margin.

GAAP net income of $ 40,496 (in thousands), or $ 0.53 per diluted share, was not representative of underlying operating performance according to the release. It was largely driven by the $65.9 million gain on sale of the Vitalware Business. The quarter also included a $ 9,494 (in thousands) loss on extinguishment of debt. After the stated non-GAAP adjustments, Adjusted Net Income (Loss) was $ (2,549) (in thousands), or $ (0.03) per basic and diluted share. For the nine-month period, the company recorded a $ 122,548 (in thousands) goodwill impairment and a net loss of $ (111,067) (in thousands).

The sale of the Vitalware Business reshaped the balance sheet and financing profile. The company reported $ 144,455 (in thousands) of proceeds from sale of business and $ (163,960) (in thousands) of debt repayment for the nine months ended September 30, 2026. Long-term debt, net of current portion, was $ — as of September 30, 2026, versus $ 151,624 (in thousands) at December 31, 2025. Cash and cash equivalents were $ 53,746 (in thousands), and net cash provided by operating activities was $ 16,911 (in thousands) for the nine-month period.

Management reaffirmed full-year 2026 guidance for total revenue of $246 million to $249 million and Adjusted EBITDA of $18 million to $18.5 million. The key reported issues remain the revenue effects of the Vitalware divestiture, DOS-to-Ignite migration headwinds, client retention, professional-services gross profitability, and the conversion of cost reductions into durable profitability.

Management, verbatim

We delivered a third quarter above the high end of our revenue and Adjusted EBITDA guidance, and we are reaffirming our full-year outlook.

Simeon Kohl, President and Chief Executive Officer

Our immediate priority is to strengthen the foundation of the business, with a focus on retaining the clients we serve and developing a path to generating durable, profitable revenue.

Simeon Kohl, President and Chief Executive Officer

Not in the filing

stated, not guessed
  • Fourth-quarter 2026 revenue and Adjusted EBITDA guidance
  • GAAP net income (loss) guidance
  • Free cash flow
  • Quarterly operating cash flow
  • Dividend declaration or payment
  • Prior-quarter comparisons for reported third-quarter metrics
  • Segment-specific year-over-year and sequential percentage changes
  • Segment-specific revenue drivers

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Background

Health Catalyst is a Nasdaq‑listed healthcare intelligence company that provides data‑driven solutions to health systems.

Company-level read

Ticker impact

$HCATNeutralHigh confidence
Context

Health Catalyst disclosed Q3 2026 results with revenue down 26% YoY and reaffirmed full-year guidance.

Expected impact

likely pressure as revenue decline and modest guidance weigh on the stock.

Evidence & confidence

The 8‑K filing is the first public disclosure of the quarter's numbers and guidance, providing fresh material for traders.

Market effects

Healthcare data‑analytics sector may see heightened scrutiny on revenue trends.

U.S. market participants focused on health‑tech earnings.

Limited to investors tracking health‑care intelligence firms.

Counterpoint

Despite revenue decline, the company’s cash position and cost‑reduction initiatives could support a rebound.

Key entities

  • Health Catalyst, Inc.

    Provider of healthcare data and analytics platforms.

  • Simeon Kohl

    President and CEO who reaffirmed guidance.

Every HCAT earnings report

This story covers one filing. The ticker page keeps them all: each quarter's reported metrics with year-over-year and sequential comparisons, segments, guidance, and how the numbers landed against the company's own prior outlook.

Related articles

$HCATMedAI 8/10

Health Catalyst (HCAT) Q2 2026 Earnings Call Transcript

Health Catalyst (HCAT) reported Q2 2026 revenue of $70.5M, down 13% from $80.7M a year earlier. Technology revenue fell to $48.8M and professional services to $21.7M. The company completed the Vitalware divestiture for $147M cash and repaid about $160M of debt. FY2026 guidance: revenue $246M-$249M and adjusted EBITDA $18M-$18.5M.

$HCATHighAI 9/10

Why Health Catalyst (HCAT) Shares Are Trading Lower Today

Health Catalyst (NASDAQ: HCAT) shares fell 23.1% after the company issued a weak Q3 revenue forecast and cut its full-year outlook. It expects Q3 revenue of $55.5 million versus $70.49 million in Q2, and reduced 2026 revenue guidance to $247.5 million at the midpoint. Q2 revenue met expectations, but the outlook pressured the stock.

$HCATMedAI 8/10

M&A: Health Catalyst Closes $147M Sale of Vitalware to Med-Metrix

Health Catalyst, Inc. said it closed the July 31, 2026 sale of Vitalware, LLC to Med-Metrix, LLC. The divestiture generated $147M in total cash consideration, subject to adjustments. Health Catalyst plans to use proceeds and cash on hand to fully repay its credit facility, removing about $19M in annual GAAP interest expense, and to focus on its core healthcare intelligence and AI platform.